JAK1 and acute lymphoblastic leukemia: Thus, in the context of T-ALL pharmacological inhibition of JAK1/JAK2 by ruxolitinib has shown therapeutic activity in ETP-ALL primary patient xenografts in vivo in both the presence and the absence of JAK-STAT mutations [140].